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and treating osteoporosis in postmenopausal women (PW). In
addition, these are the ﬁrst option of treatment (the Spanish Bone
and Mineral Society -SEIOMM) in the Clinical Practice Guide-
lines (GPC) (2003). Here, we analyse the evolution of con-
sumption of bisphosphonates and raloxifene in Spanish PW
(over 50), during the period 1999 to 2004. METHODS: A ret-
rospective analysis of the consumption was made, selecting the
four drugs for osteoporosis in PW treatment. Paget’s disease data
were not included. Drug consumption data were provided by the
Ministry of Health and Consume Database. The ﬁgures are pre-
sented as number of dispensed units (standard package), as
numbers of DDDs / 1000 PW / day, according to the ATC/DDD
system, Index 2006, and as Euros (Price to Customer tax-free) /
Dispensed DDDs / 1000 PW / day. Demographics were consulted
in the Spanish INE Database. RESULTS: The number of dis-
pensed units of Alendronate, Risedronate and Raloxifene
between 2003 and 2004 were 43.41%, 126.62%, and 19.75%,
respectively. Only Etidronate decreased, but only a 9.64%. From
among the results to emphasize the ﬁgures of DDDs / 1000 
PW / day between 2003 and 2004 that show also this increases
(15.87%, 60.18%, and 1.45% for Alendronate, Risedronate and
Raloxifene, respectively). Alendronate presented the higher cost
in 2004 (€12,297,15/DDDs/1000 PW/day. CONCLUSIONS:
The indicators used in this study have permitted establish that
dispensing data of osteoporosis in PW treatment ﬁnanced by
Spanish NHS had a signiﬁcant increase in 2004. These data coin-
cide with the implement of the Spanish GPC.
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OBJECTIVES: Adoption of new drug in medical care, a highly-
regulated industry, is and essential in terms of access to new
treatment option and raise on health care expenditure. This
study, using Cox2 as example, is to examine the diffusion of new
drug among hospitals of different characteristics. METHOD:
The data were drawn from systematic random sample of NHI
claim data in 1997 to 2001. We applied the Bass diffusion model
to analyze the monthly number of each hospital’s outpatient
clinic visits with COX2. Bass diffusion model based on the initial
time of purchase of product to explains the behavior of the dif-
fusion of the product in the market: length to reach maximum
monthly volume, maximum monthly volume, growth rate.
RESULTS: The estimates of Bass diffusion model shows that the
monthly numbers of outpatient clinic visits with COX2 pre-
scription reached the stable maximum in the 92th month, 41
months after the introduction of COX2 on April of 2001. The
length of growth period for reaching maximum volume varied
with different accreditation level of hospital: academic medical
center 38 months, metropolitan hospitals 43 months, local com-
munity hospitals 40 months, and physician clinics 51 months.
The average of maximum volume for academic center was 76.17
outpatient visits, metropolitan hospitals 87.25 visits, local com-
munity hospitals 62.65 visits, and physician clinics 34.38 visits.
Physician clinics has the fast growth rate (q = 0.1278), in con-
trast to the slowest of local community hospitals (q = 0.1159),
CONCLUSION: Hospitals of different level vary in terms of
adopting new drugs. Academic medical centers play the role of
innovators.
POS13
THE ESTIMATION OF COST–EFFECTIVENESS THRESHOLDS
PRIOR TO THE START OF LARGE CLINICAL STUDIES
Van Staa TP1, Cooper C2, Leufkens HG3
1General Practice Research Database, London, UK, 2University of
Southampton, Southampton, UK, 3Utrecht University, Utrecht,The
Netherlands
OBJECTIVES: Cost-effectiveness analyses are currently con-
ducted after the conduct of expensive clinical trials. An approach
was developed to estimate cost-effectiveness thresholds prior to
clinical studies, comparable to statistical power calculations.
METHODS: A new osteoporosis treatment was taken as
example, with different scenarios of treatment efﬁcacy and costs.
Data on fracture and mortality risks were obtained from the
General Practice Research Database. These risks were estimated
individually by age, sex, fracture history, body mass index,
smoking and other risk factors. EQ5D utilities were obtained
from a UK national report (NICE) and outcomes were simulated
over a 10-year period (5-year treatment), using a cost-
acceptability ratio of £30k per QALY gained. RESULTS: The 
5-year risk of osteoporotic fracture required to reach the cost-
effectiveness threshold was 17.1% (95% conﬁdence interval
15.0–19.3%) with a fracture efﬁcacy of 0.50 at an annual cost
of £1000. This was 6.1% (5.2–7.0%) with a cost of £250 and
3.7% (3.1–4.5% with a cost of £100. With a fracture efﬁcacy of
only 0.80, these threshold risks were 34.7% (23.2–38.7%),
10.7% (8.3–14.5%) and 5.4% (3.8–7.8%), respectively. At a T-
score of −2.5 and fracture efﬁcacy of 0.80 and cost of £250,
patients without a fracture history would require additional risk
factors (with a relative rate of 2.5) in order to reach the thresh-
old, while this would be reached by the average woman at 
age 85. However, with a cost of £1000, this threshold would
only be reached at age 55 with additional risk factors with 
RR of 9.5 and at age 85 with RR of 3.0. CONCLUSION: Cost-
effectiveness thresholds can be estimated prior to expensive clin-
ical trials using high-quality health care databases. Similar to
statistical power calculations, they can then be used to guide
patient selection into the clinical trials, by providing information
on the required minimum levels of risks.
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OBJECTIVES: To assess changes in health related quality of life
(HRQoL) in patients with osteoporotic hip fracture in Poland
using EQ-5D. METHODS: 104 patients (82 women and 22 men;
mean age 80.1 years), hospitalized between March 2004 and
March 2005, with osteoporotic hip fracture were included in a
prospective clinical trial. The inclusion criteria was: age at least
60 years, low energy femoral neck fracture or pertrochanteric
fracture of the femur and absence of severe cognitive dysfunc-
tion as measured by Hodkinson’s Abbreviated Mental Test Score.
Quality of life was measured with descriptive part of Polish
version of generic questionnaire EQ-5D. The reference European
value set (BIOMED) was used. During the ﬁrst 72 hours after
hospitalisation, patients were asked to rate their HRQoL during
the month before fracture. The follow-up took place at 10 days
and 14 months after the injury. RESULTS: Eighty three patients
were avaiable at the ﬁnal follow-up (11 were ceased and 10 lost
to follow-up). Mean EQ-5D Index increased signiﬁcantly 14
